INSM
Insmed Incorporated · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.33M | $149.97M | n/a | −2 |
| Q2 2026 | 156 | -6 | 147.06M | $15.68B | +6 | −13 |
| Q1 2026 | 166 | +6 | 152.11M | $24.63B | +9 | −4 |
| Q4 2025 | 159 | -1 | 156.45M | $27.23B | +1 | −1 |
| Q3 2025 | 21 | +1 | 121.03M | $17.43B | +1 | −1 |
| Q2 2025 | 18 | +1 | 70.35M | $7.08B | +2 | −1 |
| Q1 2025 | 14 | -1 | 33.99M | $2.59B | n/a | −1 |
| Q4 2024 | 15 | 0 | 31.46M | $2.17B | +1 | −1 |
| Q3 2024 | 14 | -1 | 23.46M | $1.71B | n/a | −1 |
| Q2 2024 | 15 | n/a | 25.91M | $1.74B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 1.27M | +190.2% | $144.59M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 58.89K | +421.1% | $5.34M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 316 | 0.0% | $34,292 | 0.0% | Held | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Assetmark, Inc | $3.72M | was 0.0% |
| Robeco Institutional Asset… | $2.78M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 664 holders, 192.22M shares, $30.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 25.00K sh · $3.10M
Director · 5.00K sh · $637,650
Officer · 239.85K sh · $31.96M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology